Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)

References

• LacourciereYAsmarRA comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan Study InvestigatorsAm J Hypertens1999121181118710619580
   PubMed Web of Science ®Google Scholar
• AnderssonOKNeldamSA comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertensionJ Hum Hypertens199711Suppl 2S63S649331011
   PubMed Web of Science ®Google Scholar
• FarsangCKawecka-JaszczKLanganJAntihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipineClin Drug Invest2001211713
   Web of Science ®Google Scholar
• HimmelmannAKeinanen-KiukaanniemiSWesterAThe effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertensionBlood Press200110435111332334
   PubMed Web of Science ®Google Scholar
• PhilippTLetzelHArensHJDose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertensionJ Hum Hypertens199711Suppl 2S67S689331013
   PubMedGoogle Scholar
• KoenigWThe Multicentre Study GroupComparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS studyClin Drug Investig200019239246
   Web of Science ®Google Scholar
• BönnerGFuchsWFixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertensionCurr Med Res Opin20042059760215140325
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet200336277277613678870
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet200336275976613678868
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet200336277778113678871
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet200336276777113678869
   PubMed Web of Science ®Google Scholar
• MogensenCENeldamSTikkanenIRandomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ20003211440144411110735
   PubMed Web of Science ®Google Scholar
• TrenkwalderPLehtovirtaMDahlKLong-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetesJ Hum Hypertens199711Suppl 2S81S839331016
   PubMedGoogle Scholar
• RossingKChristensenPKHansenBVOptimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over studyDiabetes Care20032615015512502672
   PubMed Web of Science ®Google Scholar
• RossingKJacobsenPPietraszekLRenoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trialDiabetes Care2003262268227412882847
   PubMed Web of Science ®Google Scholar
• BilousRChaturvediNSjolieAKEffect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trialsAnn Intern Med2009151112019451554
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens20032187588612714861
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAThe ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivorsStroke2003341699170312817109
   PubMed Web of Science ®Google Scholar
• ShargorodskyMHassEBoazMHigh dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure loweringAtherosclerosis200819730331017588581
   PubMed Web of Science ®Google Scholar
• BaumgartPReismannJPohlmeyerHChange from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)Dtsch Med Wochenschr200112654755011402910
   PubMed Web of Science ®Google Scholar
• ManciaGde BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2007251105118717563527
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension2003421206125214656957
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentBlood Press20091830834720001654
   PubMed Web of Science ®Google Scholar
• BramlagePSchonrockEOdojPMetabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary careBMC Cardiovasc Disord200883019000308
   PubMed Web of Science ®Google Scholar
• OparilSMichelsonELLong term efficacy, safety, and tolerability of candesartan cilexetil added to hydrochlorothiazide in patients with severe hypertensionAm J Hypertens2009120
   Google Scholar
• EdesICombination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary careClin Drug Investig200929293304
   PubMed Web of Science ®Google Scholar
• BramlagePSchonrockEOdojPImportance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZMMW Fortschr Med2008149Suppl 417218118402243
   PubMedGoogle Scholar
• UenSUnIFimmersREffect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertensionDtsch Med Wochenschr2007132818617219340
   PubMed Web of Science ®Google Scholar
• BönnerGMulticentre Study GroupAntihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapyBlood Press Suppl20082223019203019
   PubMedGoogle Scholar
• OhmaKPMilonHValnesKEfficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension: comparison with a combination of losartan and hydrochlorothiazideBlood Press2000921422011055474
   PubMed Web of Science ®Google Scholar
• KarlsonBWZetterstrandSOlofssonBA dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertensionBlood Press20091814915619462314
   PubMed Web of Science ®Google Scholar
• WaeberBVery-low-dose combination: a first-line choice for the treatment of hypertension?J Hypertens Suppl200321S3S1012929469
   PubMedGoogle Scholar
• WaeberBCombination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertensionExpert Rev Cardiovasc Ther20031435015030296
   PubMedGoogle Scholar
• BurgessEMuirheadNCotretPPthe SMART (Supra Maximal Atacand Renal Trial) InvestigatorsSupramaximal dose of candesartan in proteinuric renal diseaseJ Am Soc Nephrol20092089390019211712
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ2003326142712829555
   PubMed Web of Science ®Google Scholar
• BurnierMAngiotensin II type 1 receptor blockersCirculation200110390491211171802
   PubMed Web of Science ®Google Scholar
• SalernoCMDemopoulosLMukherjeeRCombination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertensionJ Clin Hypertens (Greenwich)2004661462015538094
   PubMedGoogle Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134586186911565518
   PubMed Web of Science ®Google Scholar
• RuggenentiPPernaAMosconiLUrinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)Kidney Int199853120912169573535
   PubMed Web of Science ®Google Scholar
• De ZeeuwDRemuzziGParvingHHAlbuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyCirculation200411092192715302780
   PubMed Web of Science ®Google Scholar
• De ZeeuwDRemuzziGParvingHHProteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALKidney Int2004652309232015149345
   PubMed Web of Science ®Google Scholar
• SchmiederRESchraderJZidekWLow-grade albuminuria and cardiovascular risk: what is the evidence?Clin Res Cardiol20079624725717453140
   PubMed Web of Science ®Google Scholar
• ManciaGde BackerGDominiczakA2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial HypertensionJ Hypertens2007251751176217762635
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens2009272121215819838131
   PubMed Web of Science ®Google Scholar
• NashDTRationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diureticsSouth Med J200710038639217458399
   PubMed Web of Science ®Google Scholar
• ConcatoJShahNHorwitzRIRandomized, controlled trials, observational studies, and the hierarchy of research designsN Engl J Med20003421887189210861325
   PubMed Web of Science ®Google Scholar